VYNE Therapeutics マネジメント

マネジメント基準チェック /24

VYNE Therapeuticsの CEO はDave Domzalskiで、 Mar2020年に任命され、の在任期間は 4.67年です。の年間総報酬は$ 2.72Mで、 23.5%給与と76.5%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.31%を直接所有しており、その価値は$ 136.77K 。経営陣と取締役会の平均在任期間はそれぞれ4.7年と3.6年です。

主要情報

Dave Domzalski

最高経営責任者

US$2.7m

報酬総額

CEO給与比率	23.5%
CEO在任期間	4.7yrs
CEOの所有権	0.3%
経営陣の平均在職期間	4.7yrs
取締役会の平均在任期間	3.6yrs

経営陣の近況

Recent updates

VYNE Therapeutics Non-GAAP EPS of -$0.13 beats by $0.02, revenue of $0.13M beats by $0.03M

Aug 12

Companies Like VYNE Therapeutics (NASDAQ:VYNE) Could Be Quite Risky

Jul 02

VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely

Mar 19

VYNE Therapeutics: Lots Of Clinical Risk Ahead And A Questionable Business Plan

Jan 13

VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely

Dec 03

Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts

Aug 13

VYNE Therapeutics: Terrible Depreciation Of Shareholder Value

Jun 30

Despite Lacking Profits VYNE Therapeutics (NASDAQ:VYNE) Seems To Be On Top Of Its Debt

Jun 07

Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts

Feb 17

Breakeven On The Horizon For VYNE Therapeutics Inc. (NASDAQ:VYNE)

Feb 10

CEO報酬分析

VYNE Therapeutics の収益と比較して、Dave Domzalski の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$34m
Jun 30 2024	n/a	n/a	-US$28m
Mar 31 2024	n/a	n/a	-US$29m
Dec 31 2023	US$3m	US$638k	-US$28m
Sep 30 2023	n/a	n/a	-US$29m
Jun 30 2023	n/a	n/a	-US$33m
Mar 31 2023	n/a	n/a	-US$31m
Dec 31 2022	US$1m	US$638k	-US$34m
Sep 30 2022	n/a	n/a	-US$35m
Jun 30 2022	n/a	n/a	-US$40m
Mar 31 2022	n/a	n/a	-US$42m
Dec 31 2021	US$5m	US$638k	-US$44m
Sep 30 2021	n/a	n/a	-US$59m
Jun 30 2021	n/a	n/a	-US$69m
Mar 31 2021	n/a	n/a	-US$226m
Dec 31 2020	US$3m	US$501k	-US$256m
Sep 30 2020	n/a	n/a	-US$270m
Jun 30 2020	n/a	n/a	-US$269m
Mar 31 2020	n/a	n/a	-US$120m
Dec 31 2019	n/a	n/a	-US$95m
Sep 30 2019	n/a	n/a	-US$71m
Jun 30 2019	n/a	n/a	-US$64m
Mar 31 2019	n/a	n/a	-US$63m
Dec 31 2018	US$1m	US$440k	-US$74m
Sep 30 2018	n/a	n/a	-US$77m
Jun 30 2018	n/a	n/a	-US$80m
Mar 31 2018	n/a	n/a	-US$77m
Dec 31 2017	US$3m	US$417k	-US$66m

報酬と市場: Daveの総報酬 ($USD 2.72M ) は、 US市場 ($USD 649.07K ) の同規模の企業の平均を上回っています。

報酬と収益: Daveの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Dave Domzalski (57 yo)

4.7yrs

在職期間

US$2,716,350

報酬

Mr. David T. Domzalski, also known as Dave, has been President, Chief Executive Officer and Director at VYNE Therapeutics Inc. (formerly known as Menlo Therapeutics Inc.). since March 9, 2020. Mr. Domzalsk...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
David Domzalski	CEO, President & Director	4.7yrs	US$2.72m	0.31% $ 136.8k
Iain Stuart	Chief Scientific Officer	4.7yrs	US$1.16m	0.055% $ 24.5k
Mutya Harsch	General Counsel	4.7yrs	US$1.13m	0.15% $ 67.5k
Tyler Zeronda	CFO & Treasurer	3.4yrs	データなし	0.89% $ 398.6k
Subhashis Banerjee	Senior Vice President of Clinical Development	less than a year	データなし	データなし
Darrell Rigel	Consultant	6yrs	US$115.20k	データなし

4.7yrs

平均在職期間

51yo

平均年齢

経験豊富な経営陣: VYNEの経営陣は経験豊富であると考えられます ( 4.7年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
David Domzalski	CEO, President & Director	4.7yrs	US$2.72m	0.31% $ 136.8k
Sharon Surrey-Barbari	Independent Non Employee Director	4.7yrs	US$116.10k	0.0071% $ 3.2k
Patrick LePore	Lead Independent Director	4.2yrs	US$123.60k	0.25% $ 110.5k
Steven Basta	Director	9.2yrs	US$83.60k	0.051% $ 22.6k
Anthony Bruno	Independent Non-Employee Director	4.7yrs	US$101.10k	0.013% $ 5.7k
Elisabeth Sandoval-Little	Independent Director	5.7yrs	US$108.60k	0% $ 0
Christine Borowski	Independent Director	less than a year	データなし	0% $ 0
Roy Fleischmann	Member of Scientific Advisory Board	3.1yrs	データなし	データなし
Martin Okun	Member of Scientific Advisory Board	3.1yrs	データなし	データなし
David Sachar	Member of Scientific Advisory Board	3.1yrs	データなし	データなし
Olaf Stuve	Member of Scientific Advisory Board	3.1yrs	データなし	データなし
Johnathan Whetstine	Member of Scientific Advisory Board	3.1yrs	データなし	データなし

3.6yrs

平均在職期間

62yo

平均年齢

経験豊富なボード: VYNEの取締役会は経験豊富であると考えられます ( 3.6年の平均在任期間)。

VYNE Therapeutics マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

VYNE Therapeutics Inc., Annual General Meeting, Dec 12, 2024

VYNE Therapeutics Inc. Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development

Lead Independent Director recently bought US$51k worth of stock

VYNE Therapeutics Inc., Annual General Meeting, Dec 13, 2023

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

Consensus EPS estimates fall by 13%

VYNE Therapeutics Inc., Annual General Meeting, Dec 12, 2024

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Share price stability

We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate

VYNE Therapeutics Announces Positive Phase 1A Sad Data for Vyn202, A Novel Bd2-Selective Bet Inhibitor

Consensus revenue estimates increase by 50%, EPS downgraded

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

VYNE Therapeutics Inc. Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development

Vyne Therapeutics Announces Dosing of First Participants in Phase 1A Trial of Novel Bd2-Selective Bet Inhibitor Vyn202

VYNE Therapeutics Inc. Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201

Consensus EPS estimates upgraded to US$0.81 loss

First quarter 2024 earnings released: US$0.15 loss per share (vs US$1.72 loss in 1Q 2023)

Vyne Therapeutics Announces FDA Clearance of IND Application for Vyn202, A Novel Bd2-Selective Bet Inhibitor

Here's Why We're Watching VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Situation

New minor risk - Share price stability

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

VYNE Therapeutics Inc. Announces Positive Biomarker Data from Successful Phase 1B Trial of VYN201 for the Treatment of Vitiligo

Consensus EPS estimates upgraded to US$4.82 loss, revenue downgraded

Lead Independent Director recently bought US$51k worth of stock

New major risk - Shareholder dilution

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

VYNE Therapeutics Inc. announced that it has received $88.151509 million in funding from Acorn Bioventures, Parkman Healthcare Partners LLC, Soleus Capital, Surveyor Capital Management, Palo Alto Investors LP and other investors

VYNE Therapeutics Inc., Annual General Meeting, Dec 13, 2023

New major risk - Share price stability

Price target increased by 21% to US$16.50

New major risk - Market cap size

Consensus revenue estimates increase by 60%, EPS downgraded

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Financial position

First quarter 2023 earnings released: US$1.72 loss per share (vs US$2.83 loss in 1Q 2022)

We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate

Full year 2022 earnings released

VYNE Therapeutics Announces Positive Results from Phase 1a Single and Multiple Ascending Dose Trial for Investigational Novel BET Inhibitor VYN201

VYNE Therapeutics Inc. Announces First Vitiligo Patient Dosed in Phase 1a/b Clinical Trial of Novel BET Inhibitor VYN201

VYNE Therapeutics Inc. announced that it has received $0.3 million in funding

VYNE Therapeutics Inc. Announces First Subjects Dosed in Phase 1a/b Clinical Trial Evaluating Pan-BET Inhibitor, VYN201, for the Treatment of Vitiligo

Consensus revenue estimates increase by 106%

Price target decreased to US$3.50

High number of new and inexperienced directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

VYNE Therapeutics Receives Non-Compliance Letter from Nasdaq

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Consensus forecasts updated

Price target decreased to US$4.00

VYNE Therapeutics Non-GAAP EPS of -$0.13 beats by $0.02, revenue of $0.13M beats by $0.03M

VYNE Therapeutics Inc. Announces Results from Its Phase 2a Trial of FMX114 for the Treatment of Mild-To-Moderate Atopic Dermatitis

Companies Like VYNE Therapeutics (NASDAQ:VYNE) Could Be Quite Risky

VYNE Therapeutics Inc. Completes Enrollment in Phase 2A Trial of FMX 114 for the Treatment of Mild-To-Moderate Atopic Dermatitis

Consensus forecasts updated

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased to US$5.80

High number of new and inexperienced directors

VYNE Therapeutics Inc. Announces Positive Phase 1b Efficacy Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis

VYNE Therapeutics Inc. Reports Positive Preclinical Data for Intra-Articular Injection of Pan-BET Inhibitor, VYN201, in an in Vivo Model of Rheumatoid Arthritis

Consensus forecasts updated

VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

VYNE Therapeutics Inc. Reports Positive Preclinical Data for Lead Bet Inhibitor, VYN201, in Human Skin Model of Vitiligo

VYNE Therapeutics Inc. Announces Phase 1B Data for Fmx114 from Phase 1B/2A Trial for the Treatment of Mild-To-Moderate Atopic Dermatitis

VYNE Therapeutics: Lots Of Clinical Risk Ahead And A Questionable Business Plan

Price target increased to US$5.80

VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely

Third quarter 2021 earnings released: US$0.41 loss per share (vs US$0.59 loss in 3Q 2020)

Consensus forecasts updated

Second quarter 2021 earnings released: US$0.39 loss per share (vs US$4.83 loss in 2Q 2020)

Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts

VYNE Therapeutics Inc. Announces Approval of Amzeeq (Minocycline) and Zilxi (Minocycline) in Chinese Economic Pilot Zone

VYNE Therapeutics Announces Initiation of Investigator Initiated Trial Evaluating AMZEEQ (Minocycline) with Oral Isotretinoin in Patients with Moderate to Severe Acne

マネジメント基準チェック /24